Pluri Inc. (NASDAQ:PLUR) Sees Large Decline in Short Interest

Pluri Inc. (NASDAQ:PLUR) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 25,800 shares, a decline of 14.0% from the February 13th total of 30,000 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily volume of 12,700 shares, the days-to-cover ratio is currently 2.0 days.

Pluri Stock Performance

Shares of NASDAQ:PLUR traded up $0.06 on Thursday, reaching $4.55. 5,405 shares of the company’s stock were exchanged, compared to its average volume of 18,050. The firm has a market capitalization of $31.84 million, a price-to-earnings ratio of -0.81 and a beta of 1.76. Pluri has a fifty-two week low of $4.07 and a fifty-two week high of $8.40. The business’s 50-day moving average is $4.46 and its two-hundred day moving average is $4.81. The company has a quick ratio of 5.04, a current ratio of 5.04 and a debt-to-equity ratio of 4.44.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative return on equity of 2,778.13% and a negative net margin of 3,551.49%.

Hedge Funds Weigh In On Pluri

An institutional investor recently raised its position in Pluri stock. Renaissance Technologies LLC grew its holdings in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,025 shares of the company’s stock after purchasing an additional 9,400 shares during the period. Renaissance Technologies LLC owned approximately 0.61% of Pluri worth $145,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.59% of the company’s stock.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.